98 results on '"Smith, Kenneth"'
Search Results
2. Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
- Author
-
Wateska, Angela R., Nowalk, Mary Patricia, Altawalbeh, Shoroq M., Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.
- Subjects
STREPTOCOCCAL disease prevention ,MEDICAL protocols ,IMMUNIZATION ,STATISTICAL models ,QUALITY-adjusted life years ,COST effectiveness ,RESEARCH funding ,AFRICAN Americans ,VACCINATION ,DECISION making ,COST benefit analysis ,VACCINATION coverage ,ATTITUDE (Psychology) ,PNEUMOCOCCAL vaccines ,VACCINE hesitancy ,HEALTH promotion ,DELPHI method - Abstract
Background: Multiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs. Methods: A Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon. Results: Uptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained. Conclusion: Current U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered. See related Editorial by Melissa K. Andrew in this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Cost-Effectiveness of Diffusion Weighted MRI Versus Planned Second-Look Surgery for Cholesteatoma.
- Author
-
Patel, Terral A., Ettyreddy, Abhinav, Cheng, Tracy, Smith, Kenneth, Sridharan, Shaum S., and McCall, Andrew A.
- Subjects
MASTOIDECTOMY ,STATISTICAL models ,QUALITY-adjusted life years ,USER charges ,COST effectiveness ,MEDICARE ,MEDICAL care ,CHOLESTEATOMA ,MAGNETIC resonance imaging ,COST benefit analysis ,DESCRIPTIVE statistics ,DECISION making ,TYMPANOPLASTY ,COMPARATIVE studies ,MEDICAID ,SENSITIVITY & specificity (Statistics) - Abstract
Objective: To compare the cost-effectiveness of serial non-echo planar diffusion weighted MRI (non-EP DW MRI) versus planned second look surgery following initial canal wall up tympanomastoidectomy for the treatment of cholesteatoma. Methods: A decision-analytic model was developed. Model inputs including residual cholesteatoma rates, rates of non-EP DW MRI positivity after surgery, and health utility scores were abstracted from published literature. Cost data were derived from the 2022 Centers for Medicare and Medicaid Services fee rates. Efficacy was defined as increase in quality-adjusted life year (QALY). One- and 2-way sensitivity analyses were performed on variables of interest to probe the model. Total time horizon was 50 years with a willingness to pay (WTP) threshold set at $50 000/QALY. Results: Base case analysis revealed that planned second-look surgery ($11 537, 17.30 QALY) and imaging surveillance with non-EP DWMRI ($10 439, 17.26 QALY) were both cost effective options. Incremental cost effectiveness ratio was $27 298/QALY, which is below the WTP threhshold. One-way sensitivity analyses showed that non-EP DW MRI was more cost effective than planned second-look surgery if the rate of residual disease after surgery increased to 48.3% or if the rate of positive MRI was below 45.9%. A probabilistic sensitivity analysis at WTP of $50 000/QALY found that second-look surgery was more cost-effective in 56.7% of iterations. Conclusion: Non-EP DW MRI surveillance is a cost-effect alternative to planned second-look surgery following primary canal wall up tympanomastoidectomy for cholesteatoma. Cholesteatoma surveillance decisions after initial canal wall up tympanomastoidectomy should be individualized. Level of Evidence: V. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy
- Author
-
Magnetta, Defne A., Kang, JaHyun, Wearden, Peter D., Smith, Kenneth J., and Feingold, Brian
- Published
- 2018
- Full Text
- View/download PDF
5. Cost-Effectiveness of Decision Support Strategies in Acute Bronchitis
- Author
-
Michaelidis, Constantinos I., Kern, Melissa S., and Smith, Kenneth J.
- Published
- 2015
- Full Text
- View/download PDF
6. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
- Author
-
Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, and Zimmerman, Richard K.
- Subjects
- *
OLDER people , *PNEUMOCOCCAL vaccines , *COST effectiveness , *VACCINE effectiveness , *QUALITY-adjusted life years - Abstract
Introduction: US pneumococcal vaccination recommendations for adults aged 65 years or older recently changed, with options for either 20-valent pneumococcal conjugate vaccine (PCV20) or the combination of 15-valent conjugate vaccine (PCV15) followed by 23-valent polysaccharide vaccine (PPSV23) 1 year later. Underserved minority adults are at higher risk for pneumococcal disease. Methods: A Markov decision analysis model estimated the incremental cost-effectiveness of the newly adopted general population pneumococcal vaccination strategies in older underserved minority adults. The model examined hypothetical 65-year-old US Black cohorts (serving as a proxy for underserved minorities) and non-Black cohorts receiving PCV20 or PCV15/PPSV23, or no vaccination. Main outcome measures included incremental cost-effectiveness per quality-adjusted life year (QALY) gained and pneumococcal disease public health outcomes. Results: Black cohorts had a greater risk of pneumococcal disease hospitalization compared to non-Black cohorts. In Black cohorts, total per person PCV20 strategy costs, compared to no vaccination, were $124 higher while gaining 0.00073 QALY, or $169,540/QALY gained. PCV15/PPSV23 cost $535,797/QALY compared to PCV20. In the non-Black cohort, PCV20 cost $210,529/QALY gained compared to no vaccination and PCV15/PPSV23 cost $728,423/QALY. Plausible variation of vaccine effectiveness minimally affected PCV20 strategy results and made PCV15/PPSV23 more unfavorable. In scenarios where the simpler one-vaccine PCV20 strategy increased absolute vaccine uptake by 10%, PCV20 cost-effectiveness changed minimally while PCV15/PPSV23 cost in excess of $6 million/QALY in the Black cohort. In probabilistic sensitivity analyses that varied all parameters simultaneously, PCV15/PPSV23 was unlikely to be favored at thresholds less than $500,000/QALY gained. Conclusion: General population recommendations for PCV20 use are substantially more economically reasonable in Black and non-Black older adult populations than PCV15/PPSV23. If using a single vaccine increases uptake, which is potentially more likely in the underserved, then PCV20 use becomes even more favorable. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Imaging versus Intervention in Managing Small Unruptured Intracranial Aneurysms: A Cost-Effectiveness Analysis.
- Author
-
Veet, Clark A., Capone, Stephen, Panczykowski, David, Parekh, Natasha, Smith, Kenneth J., Kim, Dong H., Choi, H. Alex, and Blackburn, Spiros L.
- Subjects
INTRACRANIAL arterial diseases ,INTRACRANIAL aneurysms ,PREOPERATIVE risk factors ,MAGNETIC resonance angiography ,COST effectiveness ,WATCHFUL waiting ,MEDICAL care costs - Abstract
Objective: Current guidelines recommend active surveillance with serial magnetic resonance angiography (MRA) for management of small, asymptomatic unruptured anterior circulation aneurysms (UIAs). We sought to determine the cost-effectiveness of active surveillance compared to immediate surgery. Methods: We developed a Markov cost-effectiveness model simulating patients with small (<7 mm) UIAs managed by active surveillance via MRA, immediate surgery, or watchful waiting. Inputs for the model were abstracted from the literature and used to construct a comprehensive model following persons from diagnosis to death. Outcomes were quality-adjusted life-years (QALYs), lifetime medical costs (2015 USD), and incremental cost-effectiveness ratios (ICERs). Cost-effectiveness, deterministic, and probabilistic sensitivity analyses were performed. Results: Immediate surgical treatment was the most cost-effective management strategy for small UIAs with ICER of USD 45,772 relative to active surveillance. Sensitivity analysis demonstrated immediate surgery was the preferred strategy, if rupture rate was >0.1%/year and if the diagnosis age was <70 years, while active surveillance was preferred if surgical complication risk was >11%. Probabilistic sensitivity analysis demonstrated that at a willingness-to-pay of USD 100,000/QALY, immediate surgical treatment was the most cost-effective strategy in 64% of iterations. Conclusion: Immediate surgical treatment is a cost-effective strategy for initial management of small UIAs in patients <70 years of age. While more costly than MRA, surgical treatment increased QALY. The cost-effectiveness of immediate surgery is highly sensitive to diagnosis age, rupture rate, and surgical complication risk. Though there are a wide range of rupture rates and complications associated with treatment, this analysis supports the treatment of small, unruptured anterior circulation intracranial aneurysms in patients <70 years of age. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Cost‐effectiveness of ethanol lock prophylaxis to prevent central line–associated bloodstream infections in children with intestinal failure in the United States.
- Author
-
Raghu, Vikram Kalathur, Mezoff, Ethan A., Cole, Conrad R., Rudolph, Jeffrey A., and Smith, Kenneth J.
- Subjects
CATHETER-related infections ,SCIENTIFIC observation ,ANTIBIOTIC prophylaxis ,COMPARATIVE studies ,COST effectiveness ,INTESTINAL diseases ,GOVERNMENT policy ,ETHANOL ,SENSITIVITY & specificity (Statistics) ,BLOODBORNE infections ,QUALITY-adjusted life years ,SHORT bowel syndrome ,CHILDREN - Abstract
Introduction: Central line–associated bloodstream infections (CLABSIs) lead to significant morbidity and mortality in children with intestinal failure (IF). Ethanol lock prophylaxis (ELP) greatly reduces CLABSI frequency with minimal side effects. However, in the United States, a recently approved orphan drug designation for dehydrated alcohol has greatly increased 70% ethanol cost from about $10/day to $1000/day. We examined the cost‐effectiveness of ELP in relation to these changes. Methods: We simulated a previously developed IF Markov model over 1 year. Costs were measured in 2020 US dollars and effectiveness in quality‐adjusted life‐years (QALYs). CLABSI rate with and without ELP was estimated from the largest available comparative observational study. The primary outcome was incremental cost‐effectiveness ratio (ICER) between treatments. Secondary outcomes included CLABSI frequency. Sensitivity analyses on all model parameters were performed. Results: In the base model, children with IF not using ELP accumulated $131,815 in costs and 0.32 QALYs per patient compared with $437,884 and 0.33 QALYs per patient in those using ELP. The ICER was nearly $17 million/QALY gained. ELP resulted in a 40% reduction in CLABSI frequency. ELP became cost‐effective at $68/day and cost‐saving at $63/day. Sensitivity analysis identified no other plausible parameter variation to reach the benchmark of $100,000/QALY gained. Conclusions: At the current price, ELP is not cost‐effective for CLABSI prevention in children with IF in the United States. This study highlights the critical need for the approval of an affordable lock therapy option to prevent CLABSIs in these children. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Decision Trees, EMV and Thee.
- Author
-
Smith, Kenneth F.
- Subjects
DECISION trees ,PROJECT managers ,COST effectiveness ,DECISION making - Published
- 2021
10. Influence of New Technologies on the Cost-Effectiveness of Invasive Monitoring in Epilepsy Surgery.
- Author
-
Piazza, Martin G., Smith, Kenneth J., and Abel, Taylor J.
- Subjects
- *
EPILEPSY surgery , *COST effectiveness , *PEDIATRIC surgery , *INTRAOPERATIVE monitoring - Published
- 2023
- Full Text
- View/download PDF
11. Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors.
- Author
-
Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, and Zimmerman, Richard K.
- Subjects
- *
PNEUMOCOCCAL vaccines , *OLDER people , *VACCINE effectiveness , *ADULTS , *HERD immunity , *COST effectiveness - Abstract
Introduction: Use of the 13-valent pneumococcal conjugate vaccine in nonimmunocompromised adults aged ≥65 years is controversial. Higher-valency conjugate vaccines (15-valent and 20-valent ) are under development; their potential cost effectiveness in older adults is unknown, particularly when potential indirect (herd immunity) effects from childhood vaccination are considered.Methods: A Markov model estimated the cost effectiveness of current U.S. recommendations and alternative strategies using currently available and in-development pneumococcal conjugate vaccines in seniors. Separately, strategies using a hypothetical 20-valent vaccine adding the 7 most common disease-causing non-13-valent vaccine serotypes were considered. Sensitivity analyses were performed and alternative scenarios were examined. Data were gathered and the analyses were performed in 2020.Results: In analyses considering only existing and in-development vaccines, sole 20-valent vaccine use cost $172,491/quality-adjusted life year gained compared with current U.S. recommendations under baseline assumptions (equal serotype effectiveness and no childhood vaccination indirect effects). Strategies using 15-valent vaccine were more costly and less effective. When 13-valent/20-valent vaccines were assumed ineffective against pneumococcal serotype 3 and 15-valent vaccine was fully effective, 15-valent vaccine cost $237,431/quality-adjusted life year gained. With indirect effects considered, 15-valent or 20-valent vaccine cost >$449,000/quality-adjusted life year gained. When adding hypothetical 20-valent vaccine under baseline assumptions, hypothetical 20-valent vaccine cost $139,348/quality-adjusted life year gained.Conclusions: In-development pneumococcal conjugate vaccines may be economically unreasonable in older adults, regardless of serotype effectiveness assumptions, particularly when considering potential indirect effects from use of those vaccines in children. Adult vaccines containing high-risk serotypes not contained in childhood vaccines may be more promising. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
- Author
-
Raghu, Vikram Kalathur, Rudolph, Jeffrey A, and Smith, Kenneth J
- Subjects
INTESTINE transplantation ,COMPARATIVE studies ,COST control ,COST effectiveness ,INFANT weaning ,MATHEMATICAL models ,MEDICAL care costs ,PARENTERAL feeding ,PEDIATRICS ,PEPTIDES ,PROBABILITY theory ,THEORY ,QUALITY-adjusted life years ,SHORT bowel syndrome ,DESCRIPTIVE statistics - Abstract
Background Teduglutide use in pediatric patients with short bowel syndrome can aid in the achievement of enteral autonomy, but with a price of >$400,000 per y. Objective The current study evaluated the cost-effectiveness of using teduglutide in conjunction with offering intestinal transplantation in US pediatric patients with short bowel syndrome. Design A Markov model was used to evaluate the costs (in US dollars) and effectiveness [in quality-adjusted life years (QALYs)] of using teduglutide compared with offering intestinal transplantation. Parameters were estimated from published data where available. The primary effect modeled was the probability of weaning from parenteral nutrition while on teduglutide. Sensitivity analyses were performed on all model parameters. Results Compared with offering only intestinal transplantation, adding teduglutide cost |${\$}$| 124,353/QALY gained. Reducing the cost of the medication by 16% allowed the cost to reach the typical benchmark of |${\$}$| 100,000/QALY gained. Probabilistic sensitivity analysis favored transplantation without offering teduglutide in 68% of iterations at a |${\$}$| 100,000/QALY threshold. Never using teduglutide created an opportunity cost of over |${\$}$| 100,000 per patient. Conclusions At its current price, teduglutide does not provide a cost-effective addition to transplantation in the treatment of pediatric short bowel syndrome. Further work should look to identify cost-reducing strategies, including alternative dosing regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Cost‐Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
- Author
-
Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.
- Subjects
COST effectiveness ,PNEUMOCOCCAL vaccines ,DECISION making ,IMMUNIZATION of older people ,HEALTH services accessibility ,HEALTH status indicators ,IMMUNE response ,HEALTH policy - Abstract
BACKGROUND/OBJECTIVES Recently revised vaccination recommendations for US adults, aged 65 years and older, include both 23‐valent pneumococcal polysaccharide vaccine (PPSV23) and 13‐valent pneumococcal conjugate vaccine (PCV13), with PCV13 now recommended for immunocompetent older people based on shared decision making. The public health impact and cost‐effectiveness of this recommendation or of pneumococcal vaccine uptake improvement interventions are unclear. DESIGN Markov decision analysis. SETTING AND PARTICIPANTS Hypothetical 65‐year‐old general and black population cohorts. INTERVENTION Current pneumococcal vaccination recommendations for US older people, an alternative policy omitting PCV13 in immunocompetent older people, and vaccine uptake improvement programs. RESULTS: The current pneumococcal vaccination recommendation was the most effective strategy, but afforded slight public health benefits compared to an alternative (PPSV23 for all older people plus PCV13 for the immunocompromised) and cost greater than $750 000 per quality‐adjusted life‐year (QALY) gained in either population group with a vaccine uptake improvement program (absolute uptake increase = 12.3%; cost = $1.78/eligible patient) in place. The alternative strategy was more economically favorable, but cost greater than $100 000/QALY in either population, with or without an uptake intervention. Results were robust in sensitivity analyses; however, in black older people, the alternative strategy with an uptake program was most likely to be favored in probabilistic sensitivity analyses at a $150 000/QALY gained threshold. CONCLUSION: Current pneumococcal vaccination recommendations for US older people are economically unfavorable compared to an alternative strategy omitting PCV13 in the immunocompetent. The alternative recommendation with an uptake improvement program may be economically reasonable in black population analyses and could be worth considering as a population‐wide recommendation if mitigating racial disparities is a priority. J Am Geriatr Soc 68:1271–1278, 2020. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.
- Author
-
Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.
- Subjects
ATTITUDE (Psychology) ,COST effectiveness ,DECISION making ,DELPHI method ,HEALTH promotion ,LONGITUDINAL method ,PNEUMOCOCCAL vaccines ,RACE ,VACCINATION ,DESCRIPTIVE statistics ,MIDDLE age - Abstract
In US adults aged < 65 years, pneumococcal vaccination is recommended when high-risk conditions are present, but vaccine uptake is low. Additionally, there are race-based differences in illness risk and vaccination rates. The cost-effectiveness of programs to improve vaccine uptake or of alternative vaccination policies to increase protection is unclear. A decision analysis compared, in US black and general population cohorts aged 50 years, the public health impact and cost-effectiveness of pneumococcal vaccination recommendations, without and with a vaccine uptake improvement program, and alternative population vaccine policies. Program-based uptake improvement (base case: 12.3% absolute increase, costing $1.78/eligible patient) was based on clinical trial data. US data informed population-specific pneumococcal risk. Vaccine effectiveness was estimated using Delphi panel and trial data. In both black and general population cohorts, an uptake improvement program for current vaccination recommendations was favored, costing $48,621 per QALY gained in black populations ($54,929/QALY in the general population) compared to current recommendations without a program. Alternative vaccination policies largely prevented less illness and were economically unfavorable. In sensitivity analyses, uptake programs were favored, at a $100,000/QALY threshold, unless they improved absolute vaccine uptake < 2.1% in blacks or < 2.6% in the general population. Results were robust in sensitivity analyses. Programs to increase adult pneumococcal vaccination uptake are economically reasonable compared to changes in vaccination recommendations, and more favorable in underserved minorities than in the general population. If addressing race-based health disparities is a priority, evidence-based programs to increase vaccination should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
- Author
-
Raghu, Vikram K, Binion, David G, and Smith, Kenneth J
- Subjects
COST control ,COST effectiveness ,PARENTERAL feeding ,QUALITY of life ,SHORT bowel syndrome ,GLUCAGON-like peptides ,DESCRIPTIVE statistics ,ADULTS - Abstract
Background Adults with short bowel syndrome have a high mortality and significant morbidity due to unsuccessful attempts at rehabilitation that necessitate chronic use of parenteral nutrition (PN). Teduglutide is a novel therapy that promotes intestinal adaptation to improve rehabilitation but with a price >$400,000/y. Objective The current study evaluated the cost-effectiveness of using teduglutide in US adult patients with short bowel syndrome. Methods A Markov model evaluated the costs (in US dollars) and effectiveness (in quality-adjusted life years, or QALYs) of treatment compared with no teduglutide use, with a presumed starting age of 40 y. Parameters were obtained from published data or estimation. The primary effect modeled was the increased likelihood of reduced PN days per week when using teduglutide, leading to greater quality of life and lower PN costs. Sensitivity analyses were performed on all model parameters. Results In the base scenario, teduglutide cost $949,910/QALY gained. In 1-way sensitivity analyses, only reducing teduglutide cost decreased the cost/QALY gained to below the typical threshold of $100,000/QALY gained. Specifically, teduglutide cost would need to be reduced by >65% for it to reach the threshold value. Probabilistic sensitivity analysis favored no teduglutide use in 80% of iterations at a $100,000/QALY threshold. However, teduglutide therapy was cost-saving in 13% of model iterations. Conclusions Teduglutide does not meet a traditional cost-effectiveness threshold as treatment for PN reduction in adult patients with short bowel syndrome compared with standard intestinal rehabilitation. Subpopulations that demonstrate maximum benefit could be cost-saving, and complete nonuse could lead to financial loss. Teduglutide becomes economically reasonable only if its cost is substantially reduced. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease.
- Author
-
Anderson, Alyce J. M., Ferris, Laura K., Binion, David G., and Smith, Kenneth J.
- Subjects
MELANOMA diagnosis ,INFLAMMATORY bowel diseases ,MEDICAL care costs ,SKIN examination ,QUALITY-adjusted life years ,COST effectiveness ,MELANOMA ,PREVENTIVE health services ,RESEARCH funding ,RISK assessment ,EARLY detection of cancer ,ECONOMICS ,PREVENTION - Abstract
Background and Aims: Inflammatory bowel disease (IBD) patients are at increased risk of melanoma and non-melanoma skin cancers, and preventive care guidelines in IBD favor annual skin examinations. Here we estimate the cost-effectiveness of annual melanoma screening in IBD.Methods: Melanoma screening was defined as receiving annual total body skin examinations starting at age 40 from a dermatologist. Screening was compared to US background total body skin examination rates performed by primary care practitioners. A Markov model was used to estimate intervention costs and effectiveness. Future costs and effectiveness were discounted at 3% per year over a lifetime horizon. Strategies were compared using a willingness-to-pay threshold of $100,000/quality-adjusted life year (QALY) gained.Results: Annual melanoma screening cost an average of $1961 per patient, while no screening cost $81 per patient. Melanoma screening was more effective, gaining 9.2 QALYs per 1000 persons, at a cost of $203,400/QALY gained. Screening every other year was the preferred strategy, gaining 6.2 QALYs per 1000 persons and costing $143,959/QALY. One-way sensitivity analyses suggested the relative risk of melanoma in IBD, melanoma progression, and screening costs were most influential with clinically plausible variation, leading to scenarios costing < $100,000/QALY gained. Probabilistic sensitivity analyses suggested screening every other year was cost-effective in 17.4% of iterations.Conclusions: Screening for melanoma in IBD patients was effective but expensive. Screening every other year was the most cost-effective strategy. Studies to identify IBD patients at the highest risk of developing melanoma may assist in targeting a prevention program in the most cost-effective manner. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Cost-Effectiveness Analysis of a Military Hearing Conservation Program.
- Author
-
Garcia, Seth L, Smith, Kenneth J, and Palmer, Catherine
- Subjects
- *
COST effectiveness , *NOISE pollution , *HEARING , *NOISE-induced deafness prevention , *HEALTH of military personnel , *WORKERS' compensation - Abstract
Introduction: Occupational noise threatens U.S. worker health and safety and commands a significant financial burden on state and federal government worker compensation programs. Previous studies suggest that hearing conservation programs have contributed to reduced occupational hearing loss for noise-exposed workers. Many military personnel are overexposed to noise and are provided hearing conservation services. Select military branches require all active duty personnel to follow hearing conservation program guidelines, regardless of individual noise exposure. We evaluated the cost-effectiveness of a military hearing conservation program, relative to no intervention, in relation to cases of hearing loss prevented.Methods: We employed cost-effectiveness analytic methods to compare the costs and effectiveness, in terms of hearing loss cases prevented, of a military hearing conservation program relative to no program. We used costs and probability estimates available in the literature and publicly available sources. The effectiveness of the interventions was analyzed based on whether hearing loss occurred over a 20-yr time frame.Results: The incremental cost-effectiveness ratio of the hearing conservation program compared with no intervention was $10,657 per case of hearing loss prevented. Workers were 28% less likely to sustain hearing loss in our model when they received the hearing conservation program compared with no intervention, which reflected the greater effectiveness of the hearing conservation program. Cost-effectiveness results were sensitive to estimated values for the probability of acquiring hearing loss from both interventions and the cost of hearing protection. We performed a Monte Carlo probabilistic sensitivity analysis where we simultaneously varied all the model parameters to their extreme plausible bounds. When we ran 10,000 Monte Carlo iterations, we observed that the hearing conservation program was more cost-effective in 99% of cases when decision makers were willing to pay $64,172 per case of hearing loss prevented.Conclusions: Conceding a lifetime cost for service-related compensation for hearing loss per individual of $64,172, the Department of Defense Hearing Conservation Program is an economically reasonable program relative to no intervention, if a case of hearing loss avoided costs $10,657. Considering the net difference of the costs and comparative benefits of both treatment strategies, providing a hearing conservation program for all active duty military workers may be a cost-effective intervention for the Department of Defense. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
- Author
-
Wateska, Angela R., Nowalk, Mary Patricia, Zimmerman, Richard K., Smith, Kenneth J., and Lin, Chyongchiou J.
- Subjects
COMORBIDITY ,PNEUMOCOCCAL vaccines ,INFLUENZA vaccines ,PRIMARY care ,PATIENTS ,INFLUENZA prevention ,STREPTOCOCCAL disease prevention ,PRIMARY health care ,COMPARATIVE studies ,COST effectiveness ,DECISION trees ,IMMUNIZATION ,RESEARCH methodology ,MEDICAL cooperation ,WHOOPING cough vaccines ,PUBLIC health ,RESEARCH ,RESEARCH funding ,STREPTOCOCCAL diseases ,WHOOPING cough ,EVALUATION research ,QUALITY-adjusted life years ,IMMUNOCOMPROMISED patients ,ECONOMICS ,PREVENTION - Abstract
Background: Adults aged 18-64 years with comorbid conditions are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease. The 4 Pillars™ Practice Transformation Program (4 Pillars Program) increases uptake of pneumococcal polysaccharide vaccine, influenza vaccine and tetanus-diphtheria-acellular pertussis vaccine by 5-10% among adults with high-risk medical conditions, but its cost-effectiveness is unknown.Methods: A decision tree model estimated the cost-effectiveness of implementing the 4 Pillars Program in primary care practices compared to no program for a population of adults 18-64 years of age at high risk of illness complications over a 10 year time horizon. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial in diverse practices in 2 U.S. cities. One-way and probabilistic sensitivity analyses were conducted.Results: From a third-party payer perspective, which considers direct medical costs, the 4 Pillars Program cost $28,301 per quality-adjusted life year gained; from a societal perspective, which adds direct nonmedical and indirect costs, the program was cost saving and more effective than no intervention. Cost effectiveness results favoring the program were robust in sensitivity analyses. From a public health standpoint, the model predicted that the intervention reduced influenza cases by 1.4%, with smaller decreases in pertussis and pneumococcal disease cases.Conclusion: The 4 Pillars Practice Transformation Program is an economically reasonable, and perhaps cost saving, strategy for protecting the health of adults aged < 65 years with high-risk medical conditions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial.
- Author
-
Bove, Allyn M., Smith, Kenneth J., Bise, Christopher G., Fritz, Julie M., Childs, John, Brennan, Gerard P., Abbott, J. Haxby, and Fitzgerald, G. Kelley
- Subjects
- *
COMBINED modality therapy , *COST effectiveness , *EXERCISE therapy , *KNEE diseases , *MANIPULATION therapy , *MEDICAL cooperation , *OSTEOARTHRITIS , *QUALITY of life , *QUESTIONNAIRES , *RESEARCH , *RESEARCH funding , *RANDOMIZED controlled trials , *QUALITY-adjusted life years , *TREATMENT duration - Abstract
Background. Limited information exists regarding the cost-effectiveness of rehabilitation strategies for individuals with knee osteoarthritis (OA). Objective. The study objective was to compare the cost-effectiveness of 4 different combinations of exercise, manual therapy, and booster sessions for individuals with knee OA. Design. This economic evaluation involved a cost-effectiveness analysis performed alongside a multicenter randomized controlled trial. Setting. The study took place in Pittsburgh, Pennsylvania; Salt Lake City, Utah; and San Antonio, Texas. Participants. The study participants were 300 individuals taking part in a randomized controlled trial investigating various physical therapy strategies for knee OA. Intervention. Participants were randomized into 4 treatment groups: exercise only (EX), exercise plus booster sessions (EX+B), exercise plus manual therapy (EX+MT), and exercise plus manual therapy and booster sessions (EX+MT+B). Measurements. For the 2-year base case scenario, a Markov model was constructed using the United States societal perspective and a 3% discount rate for costs and quality- adjusted life years (QALYs). Incremental cost-effectiveness ratios were calculated to compare differences in cost per QALY gained among the 4 treatment strategies. Results. In the 2-year analysis, booster strategies (EX+MT+B and EX+B) dominated no-booster strategies, with both lower health care costs and greater effectiveness. EX+ MT+B had the lowest total health care costs. EX+B cost $1061 more and gained 0.082 more QALYs than EX+MT+B, for an incremental cost-effectiveness ratio of $12,900/QALY gained. Limitations. The small number of total knee arthroplasty surgeries received by individuals in this study made the assessment of whether any particular strategy was more successful at delaying or preventing surgery in individuals with knee OA difficult. Conclusions. Spacing exercise-based physical therapy sessions over 12 months using periodic booster sessions was less costly and more effective over 2 years than strategies not containing booster sessions for individuals with knee OA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.
- Author
-
DePasse, Jay V., Smith, Kenneth J., Raviotta, Jonathan M., Shim, Eunha, Nowalk, Mary Patricia, Zimmerman, Richard K., and Brown, Shawn T.
- Subjects
- *
COST effectiveness , *INFLUENZA vaccines , *RESEARCH funding , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Offering a choice of influenza vaccine type may increase vaccine coverage and reduce disease burden, but it is more costly. This study calculated the public health impact and cost-effectiveness of 4 strategies: no choice, pediatric choice, adult choice, or choice for both age groups. Using agent-based modeling, individuals were simulated as they interacted with others, and influenza was tracked as it spread through a population in Washington, DC. Influenza vaccination coverage derived from data from the Centers for Disease Control and Prevention was increased by 6.5% (range, 3.25%-11.25%), reflecting changes due to vaccine choice. With moderate influenza infectivity, the number of cases averaged 1,117,285 for no choice, 1,083,126 for pediatric choice, 1,009,026 for adult choice, and 975,818 for choice for both age groups. Averted cases increased with increased coverage and were highest for the choice-for-both-age-groups strategy; adult choice also reduced cases in children. In cost-effectiveness analysis, choice for both age groups was dominant when choice increased vaccine coverage by ≥3.25%. Offering a choice of influenza vaccines, with reasonable resultant increases in coverage, decreased influenza cases by >100,000 with a favorable cost-effectiveness profile. Clinical trials testing the predictions made based on these simulation results and deliberation of policies and procedures to facilitate choice should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
- Author
-
Smith, Kenneth J., Zimmerman, Richard K., Nowalk, Mary Patricia, and Lin, Chyongchiou J.
- Subjects
- *
VACCINATION , *COST effectiveness , *INFLUENZA vaccines , *PNEUMOCOCCAL vaccines , *DECISION making , *IMMUNIZATION , *INFLUENZA , *MEDICAL cooperation , *WHOOPING cough vaccines , *RESEARCH , *STREPTOCOCCAL diseases , *WHOOPING cough , *QUALITY-adjusted life years , *EVALUATION of human services programs , *DESCRIPTIVE statistics , *OLD age - Abstract
Objectives To estimate the cost-effectiveness of an intervention to increase pneumococcal, influenza, and pertussis-containing vaccine uptake in adults aged 65 and older in primary care practices. Design Markov decision analysis model, comparing the cost-effectiveness of the 4 Pillars Practice Transformation Program with no intervention. Setting Diverse primary care practices in two U.S. cities. Participants Clinical trial participants aged 65 and older. Measurements Quality-adjusted life years ( QALYs), public health outcomes, and costs. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial. Other parameters were derived from the medical literature and Centers for Disease Control and Prevention data. All parameters were individually and simultaneously varied over their distributions. Results With the intervention program and extrapolating over 10 years, there would be approximately 60,920 fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses in adults aged 65 and older. Total per-person vaccination and illness costs with the intervention were $23.93 higher than without the intervention, with a concurrent increase in effectiveness of 0.0031 QALYs, or $7,635 per QALY gained. In sensitivity analyses, no individual parameter variation caused the intervention to cost more than $50,000 per QALY gained. Conclusions Implementing an intervention based on the 4 Pillars Practice Transformation Program is a cost-effective undertaking in primary care practices for individuals aged 65 and older, with predicted public health benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
- Author
-
Hernandez, Inmaculada, Smith, Kenneth J., and Zhang, Yuting
- Subjects
- *
VITAMIN K , *STROKE prevention , *ANTICOAGULANTS , *ATRIAL fibrillation , *KIDNEY physiology , *COST effectiveness , *PATIENTS , *VITAMIN therapy - Abstract
Introduction The comparative cost-effectiveness of all oral anticoagulants approved up to date has not been evaluated from the US perspective. The objective of this study was to compare the cost-effectiveness of edoxaban 60 mg, apixaban 5 mg, dabigatran 150 mg, dabigatran 110 mg, rivaroxaban 20 mg and warfarin in stroke prevention in atrial fibrillation patients at high-risk of bleeding (defined as HAS-BLED score ≥ 3). Materials and methods We constructed a Markov state-transition model to evaluate lifetime costs and quality-adjusted life years (QALYs) with each of the six treatments from the perspective of US third-party payers. Probabilities of clinical events were obtained from the RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI trials; costs were derived from the Healthcare Cost and Utilization Project, and other studies. Because edoxaban is only indicated in patients with creatinine clearance ≤ 95 ml/min, we re-ran our analyses after excluding edoxaban from the analysis. Results Treatment with edoxaban 60 mg cost $77,565/QALY gained compared to warfarin, and apixaban 5 mg cost $108,631/QALY gained compared to edoxaban 60 mg. When edoxaban was not included in the analysis, treatment with apixaban 5 mg cost $84,128/QALY gained, compared to warfarin. Dabigatran 150 mg, dabigatran 110 mg and rivaroxaban 20 mg were dominated strategies. Conclusions For patients with creatinine clearance between 50 and 95 ml/min, apixaban 5 mg was the most cost-effective treatment for willingness-to-pay thresholds (WTP) above $115,000/QALY gained, and edoxaban 60 mg was cost-effective when the WTP was between $75,000 and $115,000/QALY gained. For patients with creatinine clearance > 95 ml/min, apixaban 5 mg was the most cost-effective treatment for WTP thresholds above $80,000/QALY gained. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Cost-effectiveness of workplace wellness to prevent cardiovascular events among U.S. firefighters.
- Author
-
Patterson, P. Daniel, Smith, Kenneth J., and Hostler, David
- Subjects
HEALTH of fire fighters ,CARDIOVASCULAR diseases ,PHYSICAL fitness ,COST effectiveness ,INDUSTRIAL hygiene ,MYOCARDIAL infarction - Abstract
Background: The leading cause of death among firefighters in the United States (U.S.) is cardiovascular events (CVEs) such as sudden cardiac arrest and myocardial infarction. This study compared the cost-effectiveness of three strategies to prevent CVEs among firefighters. Methods: We used a cost-effectiveness analysis model with published observational and clinical data, and cost quotes for physiologic monitoring devices to determine the cost-effectiveness of three CVE prevention strategies. We adopted the fire department administrator perspective and varied parameter estimates in one-way and two-way sensitivity analyses. Results: A wellness-fitness program prevented 10% of CVEs, for an event rate of 0.9% at $1440 over 10-years, or an incremental cost-effectiveness ratio of $1.44 million per CVE prevented compared to no program. In one-way sensitivity analyses, monitoring was favored if costs were < $116/year. In two-way sensitivity analyses, monitoring was not favored if cost was ≥ $399/year. A wellness-fitness program was not favored if its preventive relative risk was >0.928. Conclusions: Wellness-fitness programs may be a cost-effective solution to preventing CVE among firefighters compared to real-time physiologic monitoring or doing nothing. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
- Author
-
Raviotta, Jonathan M., Smith, Kenneth J., DePasse, Jay, Brown, Shawn T., Shim, Eunha, Nowalk, Mary Patricia, and Zimmerman, Richard K.
- Subjects
- *
INFLUENZA diagnosis , *COMPARATIVE studies , *COST effectiveness , *IMMUNIZATION , *INFLUENZA , *PUBLIC health , *INFLUENZA vaccines , *RESEARCH funding , *TREATMENT effectiveness , *QUALITY-adjusted life years , *DESCRIPTIVE statistics , *OLD age , *ECONOMICS - Abstract
Objectives To compare the cost-effectiveness of four influenza vaccines available in the United States for persons aged 65 and older: trivalent inactivated influenza vaccine ( IIV3), quadrivalent inactivated influenza vaccine ( IIV4), a more-expensive high-dose IIV3, and a newly approved adjuvanted IIV3. Design Cost-effectiveness analysis using a Markov model and sensitivity analyses. Setting A hypothetical influenza vaccination season modeled according to possible U.S. influenza vaccination policies. Participants Hypothetical cohort of individuals aged 65 and older in the United States. Measurements Cost-effectiveness and public health benefits of available influenza vaccination strategies in U.S. elderly adults. Results IIV3 cost $3,690 per quality-adjusted life year ( QALY) gained, IIV4 cost $20,939 more than IIV3 per QALY gained, and high-dose IIV3 cost $31,214 more per QALY than IIV4. The model projected 83,775 fewer influenza cases and 980 fewer deaths with high-dose IIV3 than with the next most-effective vaccine: IIV4. In a probabilistic sensitivity analysis, high-dose IIV3 was the favored strategy if willingness to pay is $25,000 or more per QALY gained. Adjuvanted IIV3 cost-effectiveness depends on its price and effectiveness (neither yet determined in the United States) but could be favored if its relative effectiveness is 15% greater than that of IIV3. Conclusion From economic and public health standpoints, high-dose IIV3 for adults aged 65 years and older is likely to be favored over the other vaccines, based on currently available data. The cost-effectiveness of adjuvanted IIV3 should be reviewed after its effectiveness has been compared with that of other vaccines and its U.S. price is established. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular risk.
- Author
-
Smith, Kenneth J., Kuo, Shihchen, Zgibor, Janice C., McTigue, Kathleen M., Hess, Rachel, Bhargava, Tina, and Bryce, Cindy L.
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *PRIMARY care , *DIGITAL resources in public health , *COUNSELING , *OBESITY , *DIABETES prevention , *TYPE 2 diabetes prevention , *COMPARATIVE studies , *COST effectiveness , *EXERCISE , *HEALTH promotion , *HYPERTENSION , *INTERNET , *RESEARCH methodology , *MEDICAL care , *MEDICAL cooperation , *PRIMARY health care , *RESEARCH , *EVALUATION research , *LIFESTYLES , *QUALITY-adjusted life years , *ECONOMICS - Abstract
Objective: To assess the cost-effectiveness of an online adaptation of the diabetes prevention program (ODPP) lifestyle intervention.Methods: ODPP was a before-after evaluation of a weight loss intervention comprising 16 weekly and 8 monthly lessons, incorporating behavioral tools and regular, brief, web-based individualized counseling in an overweight/obese cohort (mean age 52, 76% female, 92% white, 28% with diabetes). A Markov model was developed to estimate ODPP cost effectiveness compared with usual care (UC) to reduce metabolic risk over 10years. Intervention costs and weight change outcomes were obtained from the study; other model parameters were based on published reports. In the model, diabetes risk was a function of weight change with and without the intervention.Results: Compared to UC, the ODPP in our cohort cost $14,351 and $29,331 per quality-adjusted life-year (QALY) gained from the health care system and societal perspectives, respectively. In a hypothetical cohort without diabetes, the ODPP cost $7777 and $18,263 per QALY gained, respectively. Results were robust in sensitivity analyses, but enrolling cohorts with lower annual risk of developing diabetes (≤1.8%), enrolling fewer participants (≤15), or increasing the hourly cost (≥$91.20) or annual per-participant time (≥1.45h) required for technical support could increase ODPP cost to >$20,000 per QALY gained. In probabilistic sensitivity analyses, ODPP was cost-effective in 20-58% of model iterations using an acceptability threshold of $20,000, 73-92% at $50,000, and 95-99% at $100,000 per QALY gained.Conclusions: The ODPP may offer an economical approach to combating overweight and obesity. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.
- Author
-
Smith, Kenneth J., Raviotta, Jonathan M., DePasse, Jay V., Brown, Shawn T., Shim, Eunha, Patricia Nowalk, Mary, and Zimmerman, Richard K.
- Subjects
- *
COST effectiveness , *INFLUENZA vaccines , *VACCINATION of children , *VIRUS inactivation , *QUALITY-adjusted life years , *MARKOV processes , *INFLUENZA prevention , *INFLUENZA , *COMPARATIVE studies , *IMMUNIZATION , *RESEARCH methodology , *MEDICAL cooperation , *PROBABILITY theory , *RESEARCH , *RESEARCH funding , *EVALUATION research , *VACCINES , *ECONOMICS - Abstract
Introduction: Prior evidence found live attenuated influenza vaccine (LAIV) more effective than inactivated influenza vaccine (IIV) in children aged 2-8 years, leading CDC in 2014 to prefer LAIV use in this group. However, since 2013, LAIV has not proven superior, leading CDC in 2015 to rescind their LAIV preference statement. Here, the cost effectiveness of preferred LAIV use compared with IIV in children aged 2-8 years is estimated.Methods: A Markov model estimated vaccination strategy cost effectiveness in terms of cost per quality-adjusted life-year gained. Base case assumptions were equal vaccine uptake; IIV use when LAIV was not indicated (in 11.7% of the cohort); and no indirect vaccination effects. Sensitivity analyses included estimates of indirect effects from both equation- and agent-based models. Analyses were performed in 2014-2015.Results: Using prior effectiveness data in children aged 2-8 years (LAIV=83%, IIV=64%), preferred LAIV use was less costly and more effective than IIV (dominant), with results sensitive only to LAIV and IIV effectiveness variation. Using 2014-2015 U.S. effectiveness data (LAIV=0%, IIV=15%), IIV was dominant. In two-way sensitivity analyses, LAIV use was cost saving over the entire range of IIV effectiveness (0%-81%) when absolute LAIV effectiveness was >7.1% higher than IIV, but never cost saving when absolute LAIV effectiveness was <3.5% higher than IIV.Conclusions: Results support CDC's decision to no longer prefer LAIV use and provide guidance on effectiveness differences between influenza vaccines that might lead to preferential LAIV recommendation for children aged 2-8 years. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults.
- Author
-
Michaelidis, Constantinos, Zimmerman, Richard, Nowalk, Mary, Fine, Michael, and Smith, Kenneth
- Subjects
ANTIBIOTICS ,COST effectiveness ,RESPIRATORY infections ,OUTPATIENT medical care ,COHORT analysis ,WILLINGNESS to pay - Abstract
BACKGROUND: Two clinical trials suggest that procalcitonin-guided antibiotic therapy can safely reduce antibiotic prescribing in outpatient management of acute respiratory tract infections (ARTIs) in adults. Yet, it remains unclear whether procalcitonin testing is cost-effective in this setting. OBJECTIVE: To evaluate the cost-effectiveness of procalcitonin-guided antibiotic therapy in outpatient management of ARTIs in adults. DESIGN: Cost-effectiveness model based on results from two published European clinical trials, with all parameters varied widely in sensitivity analyses. PATIENTS: Two hypothetical cohorts were modeled in separate trial-based analyses: adults with ARTIs judged by their physicians to require antibiotics and all adults with ARTIs. INTERVENTIONS: Procalcitonin-guided antibiotic therapy protocols versus usual care. MAIN MEASURES: Costs and cost per antibiotic prescription safely avoided. KEY RESULTS: We estimated the health care system willingness-to-pay threshold as $43 (range $0-$333) per antibiotic safely avoided, reflecting the estimated cost of antibiotic resistance per outpatient antibiotic prescribed. In the cohort including all adult ARTIs judged to require antibiotics by their physicians, procalcitonin cost $31 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored compared to usual care was 58.4 % in a probabilistic sensitivity analysis. In the analysis that included all adult ARTIs, procalcitonin cost $149 per antibiotic prescription safely avoided and the likelihood of procalcitonin use being favored was 2.8 %. CONCLUSIONS: Procalcitonin-guided antibiotic therapy for outpatient management of ARTIs in adults would be cost-effective when the costs of antibiotic resistance are considered and procalcitonin testing is limited to adults with ARTIs judged by their physicians to require antibiotics. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective.
- Author
-
Seaman, Craig D., Smith, Kenneth J., and Ragni, Margaret V.
- Subjects
- *
RIVAROXABAN , *WARFARIN , *BLOOD coagulation , *COST effectiveness , *THROMBOEMBOLISM , *PUBLIC health - Abstract
Abstract: Introduction: Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in the prevention of recurrent venous thromboembolism (VTE). Whether rivaroxaban is cost-effective in the prevention of recurrent VTE, however, is not known. Material and Methods: To assess the cost effectiveness of rivaroxaban compared with warfarin in the prevention of recurrent VTE, we built a Markov state-transition model over a 10-year time horizon. The base case analysis consisted of a hypothetical cohort of 60-year-old patients with an initial VTE who received secondary prophylaxis with either rivaroxaban or warfarin for 3 to 12months. Cost estimates were derived from the Healthcare and Utilization Project and other sources. Probabilities were based on literature values. Outcomes included costs in 2011 United States dollars, quality-adjusted life-years (QALYs), and incremental cost effectiveness ratios (ICERs) over 10years from a societal perspective. Results: Compared with warfarin, the rivaroxaban strategy cost less ($3,195 vs. $6,188) and was more effective (9.29 QALYs vs 9.14 QALYs). Our results were highly robust in sensitivity analyses. Warfarin was no longer dominated by rivaroxaban when the risk of major bleeding with rivaroxaban exceeds 3.8% (base case estimate: 0.96%). Conclusion: In summary, prophylactic anticoagulation with rivaroxaban appears to be a cost effective, and perhaps cost saving, alternative to warfarin for the prevention of recurrent VTE. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia.
- Author
-
Smith, Kenneth, Wateska, Angela, Nowalk, M., Raymund, Mahlon, Lee, Bruce, Zimmerman, Richard, and Fine, Michael
- Subjects
- *
COST effectiveness , *CALCITONIN , *ANTIBIOTICS , *PNEUMONIA treatment , *DECISION making , *CLINICAL trials , *THERAPEUTICS - Abstract
BACKGROUND: Although prior randomized trials have demonstrated that procalcitonin-guided antibiotic therapy effectively reduces antibiotic use in patients with community-acquired pneumonia (CAP), uncertainties remain regarding use of procalcitonin protocols in practice. OBJECTIVE: To estimate the cost-effectiveness of procalcitonin protocols in CAP. DESIGN: Decision analysis using published observational and clinical trial data, with variation of all parameter values in sensitivity analyses. PATIENTS: Hypothetical patient cohorts who were hospitalized for CAP. INTERVENTIONS: Procalcitonin protocols vs. usual care. MAIN MEASURES: Costs and cost per quality adjusted life year gained. KEY RESULTS: When no differences in clinical outcomes were assumed, consistent with clinical trials and observational data, procalcitonin protocols cost $10-$54 more per patient than usual care in CAP patients. Under these assumptions, results were most sensitive to variations in: antibiotic cost, the likelihood that antibiotic therapy was initiated less frequently or over shorter durations, and the likelihood that physicians were nonadherent to procalcitonin protocols. Probabilistic sensitivity analyses, incorporating procalcitonin protocol-related changes in quality of life, found that protocol use was unlikely to be economically reasonable if physician protocol nonadherence was high, as observational study data suggest. However, procalcitonin protocols were favored if they decreased hospital length of stay. CONCLUSIONS: Procalcitonin protocol use in hospitalized CAP patients, although promising, lacks physician nonadherence and resource use data in routine care settings, which are needed to evaluate its potential role in patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
30. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.
- Author
-
Smith, Kenneth J., Nowalk, Mary Patricia, Raymund, Mahlon, and Zimmerman, Richard K.
- Subjects
- *
PNEUMOCOCCAL vaccines , *IMMUNOCOMPROMISED patients , *VACCINATION of adults , *HIV-positive persons , *DECISION making in clinical medicine , *COST effectiveness - Abstract
Highlights: [•] Pneumococcal vaccination cost-effectiveness in immunocompromised adults is unclear. [•] We estimated, using decision analysis, the cost-effectiveness of vaccination strategies. [•] In all immunocompromised, a single PCV13 was favored over other strategies. [•] In the HIV-infected subgroup, using both PCV13 and PPSV23 was favored. [•] PCV13 alone may be more economically reasonable in many immunocompromised persons. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults
- Author
-
Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Raymund, Mahlon, Lee, Bruce Y., and Zimmerman, Richard K.
- Subjects
- *
PNEUMOCOCCAL vaccines , *HEALTH planning , *OLDER people , *MARKOV processes , *COST effectiveness , *MEDICAL care costs , *DRUG dosage - Abstract
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by the U.S. Food and Drug Administration for adults, but its role in older adults is unclear. Purpose: To compare PCV13 strategies to currently recommended vaccination strategies in adults aged ≥65 years. Methods: Using a Markov model, the cost effectiveness of PCV13 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23), alone or in combination, was estimated, in adults aged either 65 years or 75 years. No prior vaccination, prior vaccination, and vaccine hyporesponsiveness scenarios were examined. Pneumococcal disease rates, indirect childhood PCV13 effects, and costs were estimated using CDC Active Bacterial Core surveillance data and U.S. national databases. An expert panel estimated vaccine-related protection. A societal perspective was taken and outcomes were discounted 3% per year. Results: In those aged 65 years, single-dose PCV13 cost $11,300 per quality-adjusted life-year (QALY) gained compared to no vaccination; at ages 65 and 80 years, PCV13 cost $83,000/QALY. In those aged 75 years, single-dose PCV13 cost $62,800/QALY gained. PPSV23 cost more and was less effective than PCV13. Results were sensitive to varying vaccine effectiveness and indirect effect estimates. In hyporesponsiveness scenarios, cost-effectiveness ratios increased by 37%–78% for single-dose strategies and 29%–35% for multiple-dose strategies. Conclusions: Single-dose PCV13 strategies are likely to be economically reasonable in older adults. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
32. Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine.
- Author
-
Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Raymund, Mahlon, Nuorti, J. Pekka, and Zimmerman, Richard K.
- Subjects
- *
PNEUMOCOCCAL vaccines , *COST effectiveness , *POLYSACCHARIDES , *MARKOV processes , *LUNG diseases - Abstract
The article discusses a study of the cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults in the U.S. A Markov state-transition model was used to examine pneumococcal vaccination strategies. Results indicate that PCV13 administered at ages 50 and 65 years can reduce pneumococcal disease burden in an economically reasonable manner. Also noted is the low-range estimate of the PPSV23 effectiveness against invasive pneumococcal disease (IPD). One of the study limitations is the lack of data on PCV13 effectiveness.
- Published
- 2012
- Full Text
- View/download PDF
33. The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model.
- Author
-
Heilbrun, Marta E., Yu, Junhua, Smith, Kenneth J., Dechet, Christopher B., Zagoria, Ronald J., and Roberts, Mark S.
- Subjects
KIDNEY disease diagnosis ,KIDNEY disease treatments ,BIOPSY ,MARKOV processes ,WILLINGNESS to pay ,COST effectiveness ,COHORT analysis - Abstract
Purpose: The most effective diagnostic strategy for the very small, incidentally detected solid renal mass is uncertain. We assessed the cost-effectiveness of adding percutaneous biopsy or active surveillance to the diagnosis of a 2 cm or less solid renal mass. Materials and Methods: A Markov state transition model was developed to observe a hypothetical cohort of healthy 60-year-old men with an incidentally detected, 2 or less cm solid renal mass, comparing percutaneous biopsy, immediate treatment and active surveillance. The primary outcomes assessed were the incremental cost-effectiveness ratio measured by cost per life-year gained at a willingness to pay threshold of $50,000. Model results were assessed by sensitivity analysis. Results: Immediate treatment was the highest cost, most effective diagnostic strategy, providing the longest overall survival of 18.53 life-years. Active surveillance was the lowest cost, least effective diagnostic strategy. On cost-effectiveness analysis using a societal willingness to pay threshold of $50,000 active surveillance was the preferred choice at a $75,000 willingness to pay threshold while biopsy and treatment were acceptable ($56,644 and $70,149 per life-year, respectively). When analysis was adjusted for quality of life, biopsy dominated immediate treatment as the most cost-effective diagnostic strategy at $33,840 per quality adjusted life-year gained. Conclusions: Percutaneous biopsy may have a greater role in optimizing the diagnosis of an incidentally detected, 2 cm or less solid renal mass. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
34. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds
- Author
-
Smith, Kenneth J., Lee, Bruce Y., Nowalk, Mary Patricia, Raymund, Mahlon, and Zimmerman, Richard K.
- Subjects
- *
COST effectiveness , *INFLUENZA vaccines , *PNEUMOCOCCAL vaccines , *VACCINATION of adults , *MEDICAL care for older people , *COMORBIDITY , *MARKOV processes , *SENSITIVITY analysis , *TREATMENT effectiveness - Abstract
Abstract: Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
35. Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine.
- Author
-
Junhua Yu, Smith, Kenneth J., and Brixner, Diana I.
- Subjects
- *
MIGRAINE prevention , *DRUG therapy , *COST effectiveness , *CLINICAL trials , *DRUG side effects , *PROPRANOLOL - Abstract
Background: There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. Objective: To compare the cost effectiveness of adding preventive treatment to abortive therapy for acute migraine with abortive therapy for acute migraine alone in the primary care setting. Methods: A Markov decision analytic model with a cycle length of 1 day, a time horizon of 365 days and three health states was used to perform an analysis comparing the cost effectiveness and utility of live treatments for migraine prophylaxis (amitriptyline 75mg/day, topiramate 100 and 200mg/day, timolol 20 mg/day, divalproex sodium 1000 mg/day or propranolol 160 mg/day) with treatment of acute migraine alone for the management of migraine in the primary care setting. One-way and probabilistic sensitivity analyses were performed to test the robustness of the results. Results: The expected total annual cost for the use of preventive agents ranged from $US2932 to $US3887, compared with $US3960 for the use of abortive medications only. In the baseline analysis, use of each of the five preventive agents generated more quality-adjusted life-years (QALY5) and incurred lower costs compared with abortive medications only. Monte Carlo Simulation suggested that amitriptyline 75 mg/day was most likely to be considered a cost-effective option versus the other five therapies, followed by timolol 20mg/day, topiramate 200mg/day, topiramate 100mg/day, divalproex sodium 1000mg/day and propranolol 160mg/day when the willingness-to-pay (WTP) for society is <$US18 000 per QALY gained. Conclusions: Preventive medications appear to be a cost-effective approach to the management of migraine in the primary care setting compared with the approach of abortive treatment only. Among those preventive agents, probabilistic sensitivity analysis suggests that, when the societal WTP is
- Published
- 2010
- Full Text
- View/download PDF
36. Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement.
- Author
-
Kapoor, Alok, Warren Chuang, Nila Radhakrishnan, Smith, Kenneth J., Berlowitz, Dan, Segal, Jodi B., Katz, Jeffrey N., and Losina, Elena
- Subjects
THROMBOEMBOLISM ,TOTAL hip replacement ,TOTAL knee replacement ,ARTHROPLASTY ,ARTIFICIAL hip joints ,COST effectiveness ,HEPARIN - Abstract
Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE prophylaxis regimens for THR and TKR. We searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS Economic Evaluation Database (1997 to October 2009). We analysed recent cost-effectiveness studies examining five categories of comparisons: (i) anticoagulants (warfarin, low-molecular-weight heparin [LMWH] or fondaparinux) versus acetylsalicylic acid (aspirin); (ii) LMWH versus warfarin; (iii) fondaparinux versus LMWH; (iv) comparisons with new oral anticoagulants; and (v) extended-duration (≥3 weeks) versus shortduration (<3 weeks) prophylaxis. We abstracted information on cost and effectiveness for each prophylaxis regimen in order to calculate an incremental cost-effectiveness ratio. Because of variations in effectiveness units reported and horizon length analysed, we calculated two cost-effectiveness ratios, one for the number of symptomatic VTE events avoided at 90 days and the other for QALYs at the 1-year mark or beyond. Our search identified 33 studies with 67 comparisons. After standardization, comparisons between LMWH and warfarin were inconclusive, whereas fondaparinux dominated LMWH in nearly every comparison. The latter results were derived from radiographic VTE rates. Extended-duration prophylaxis after THR was generally cost effective. Small numbers prohibit conclusions about aspirin, new oral anticoagulants or extended-duration prophylaxis after TKR. Fondaparinux after both THR and TKR and extended-duration LMWH after THR appear to be cost-effective prophylaxis regimens. Small numbers for other comparisons and absence of trials reporting symptomatic endpoints prohibit comprehensive conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
37. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis
- Author
-
Smith, Kenneth J., Zimmerman, Richard K., Nowalk, Mary Patricia, and Roberts, Mark S.
- Subjects
- *
DRUG tolerance , *PNEUMOCOCCAL vaccines , *BACTERIAL vaccines , *VACCINATION , *COST effectiveness , *POLYSACCHARIDES , *COHORT analysis , *DRUG efficacy , *DRUG design , *THERAPEUTICS - Abstract
Abstract: Optimal pneumococcal polysaccharide vaccination (PPV) policy is unknown for cohorts aged ≥65 years. Using a Markov model, we estimated the cost-effectiveness of single- and multiple-dose PPV strategies in 65-, 75-, and 80-year-old cohorts. PPV at age 65 cost $26,100 per QALY (quality adjusted life years) gained. Vaccination at ages 75 and 80 cost $71,300–75,800 per QALY; revaccination strategies cost more. When prior vaccination and loss of vaccine effectiveness due to tolerance are assumed, cost-effectiveness ratios increase substantially. Single-dose PPV is worth considering in patients aged 65–80 from clinical and economic standpoints. Revaccination strategies for the elderly are less cost-effective, particularly when prior vaccination and vaccine tolerance are considered. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
38. Cost-Effectiveness of Alternative Outpatient Pelvic Inflammatory Disease Treatment Strategies.
- Author
-
Smith, Kenneth J., Ness, Roberta B., Wiesenfeld, Harold C., and Roberts, Mark S.
- Subjects
- *
COST effectiveness , *DRUG prices , *ANTIBIOTICS , *COST analysis , *MEDICAL care costs , *PELVIC inflammatory disease treatment , *ANTI-infective agents , *THERAPEUTICS - Abstract
The article examines the role of antibiotic costs on the cost-effectiveness of Pelvic Inflammatory Disease (PID) therapy in the U.S. To estimate the incremental cost-effectiveness of the outpatient antibiotic regimens for PID, researchers used a Markov decision model to calculate incremental costs per Quality Adjusted Life Year (QALY). They discovered that antibiotic costs vary between $43 (ceftriaxone and doxycycline) and $188 (ofloxacin/metronidazole). They hypothesize that if the more expensive of these antibiotics decreases the relative risk of PID complications by 1%, then ofloxacin/metronidazole costs $30,200 per QALY gained.
- Published
- 2007
- Full Text
- View/download PDF
39. Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism.
- Author
-
Aujesky, Drahomir, Smith, Kenneth J., Cornuz, Jacques, and Roberts, Mark S.
- Subjects
- *
HEPARIN , *ANTICOAGULANTS , *DRUG prices , *PULMONARY embolism , *ARTERIAL occlusions , *COST effectiveness , *MEDICAL care costs - Abstract
This article cites a study confirming the cost-effectiveness of low-molecular-weight heparin (LMWH) for the treatment of pulmonary embolism (PE). LMWH has been considered safe and effective for treating PE. A Markov state-transition model was developed in this study to evaluate the medical and economic outcomes of a 6-day course with fixed-dose LMWH or adjusted-dose unfractionated heparin (UFH) in a hypothetical cohort of 60-year-old patients with acute submassive PE. Researchers have performed a secondary analysis in which different proportions of patients receiving LMWH were discharged early or treated entirely as outpatients. It was noticed that, while the lifetime cost of UFH was lower than that of LMWH, the mean life expectancy of UFH-treated patients was also lower than that of LMWH-treated patients both in terms of unadjusted years and quality-adjusted years.
- Published
- 2005
- Full Text
- View/download PDF
40. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event
- Author
-
Aujesky, Drahomir, Smith, Kenneth J., and Roberts, Mark S.
- Subjects
- *
WARFARIN , *OLDER men , *OLDER women , *COUMARINS - Abstract
Abstract: Purpose: The optimal duration and intensity of warfarin therapy after a first idiopathic venous thromboembolic event are uncertain. We used decision analysis to evaluate clinical and economic outcomes of different anticoagulation strategies with warfarin. Methods: We built a Markov model to assess 6 strategies to treat 40- to 80-year-old men and women after their first idiopathic venous thromboembolic event: 3-month, 6-month, 12-month, 24-month, and unlimited-duration conventional-intensity anticoagulation (International Normalized Ratio, 2–3) and unlimited-duration low-intensity anticoagulation (International Normalized Ratio, 1.5-2). The model incorporated age- and sex-specific clinical parameters, utilities, and costs. Using a societal perspective, we compared strategies based on quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios. Results: In our baseline analysis, incremental cost-effectiveness ratios were lower in younger patients and in men, reflecting the higher bleeding risk at older ages, and the lower risk of recurrence among women. Based on a willingness-to-pay of <$50000/QALY, the 24-month strategy was most cost-effective in 40-year-old men ($48805/QALY), while the 6-month strategy was preferred in 40-year-old women ($35977/QALY) and 60-year-old men ($29878/QALY). In patients aged ≥80 years, 3-month anticoagulation was less costly and more effective than other strategies. Cost-effectiveness results were influenced by the risks associated with recurrent venous thromboembolism, the major bleeding risk of conventional-intensity anticoagulation and the disutility of taking warfarin. Conclusion: Longer initial conventional-intensity anticoagulation is cost-effective in younger patients while 3 months of anticoagulation is preferred in elderly patients. Patient age, sex, clinical factors, and patient preferences should be incorporated into medical decision making when selecting an appropriate anticoagulation strategy. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
41. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
- Author
-
Smith, Kenneth J., Roberts, Mark S., Smith, K J, and Roberts, M S
- Subjects
- *
CHICKENPOX , *VACCINATION , *COST effectiveness - Abstract
Purpose: Some authorities recommend varicella antibody testing or vaccination for adults without a history of chickenpox, but the cost effectiveness of these interventions is uncertain.Subjects and Methods: Using a Markov decision model, we estimated the cost effectiveness of three strategies for adults with no history of chickenpox: no vaccination, varicella antibody testing followed by vaccination for those without antibody, and vaccinating all. Societal and third-party payer perspectives were taken, with costs and benefits discounted at 3% per year. Assumptions for the baseline analysis were chosen to bias against no vaccination.Results: In the baseline analysis for 20- to 29-year-old patients, testing followed by vaccination compared with no vaccination is cost saving from a societal perspective and costs $6,670 per quality-adjusted life-year (QALY) gained from a third-party payer perspective. When less favorable assumptions are used, results are sensitive to the rates of compliance with vaccination follow-up; testing followed by vaccination costs more than $50,000 per QALY if <75% comply. For patients 30 years of age and older, the incremental cost of testing followed by vaccination is at least $97,100 per QALY compared with no vaccination, with costs greater than $50,000 per QALY unless testing costs less than $7.73, the chickenpox case-fatality rate is >0.067% (baseline 0.025%), or immunity with no chickenpox history is <25% (baseline 71%). In either age group, vaccinating all has an incremental cost of $2 to $16 million per QALY gained compared with testing followed by vaccination.Conclusion: Testing followed by vaccination for varicella in US adults aged 20 to 29 years may be cost effective by conventional criteria but is sensitive to rates of compliance with vaccination protocols. Testing or vaccination of older adults is expensive but may be cost effective in patients with lower probabilities of immunity or in those who have a greater risk of complications from chickenpox. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
42. FINANCIAL EFFECTIVENESS OF A CORPORATE WEIGHT LOSS PROGRAM.
- Author
-
Smith, Kenneth J., Timothy Haight, G., and Everly, Jr., George S.
- Subjects
COST effectiveness ,CASE studies ,INDUSTRIAL costs ,COST analysis ,SHADOW prices ,INDUSTRIAL management - Abstract
This study examined the financial effectiveness of a corporate weight loss program. Case study data are presented which illustrate the cost effectiveness of the program. [ABSTRACT FROM AUTHOR]
- Published
- 1988
- Full Text
- View/download PDF
43. Differential Cost Analysis Techniques in Occupational Health Promotion Evaluation.
- Author
-
Smith, Kenneth J.
- Subjects
MEDICAL care costs ,EMPLOYEE health promotion ,OCCUPATIONAL health services ,COST accounting ,COST analysis ,COST effectiveness - Abstract
The article reports on the application of differential cost analysis techniques to worksite-based health promotion programs in the United States. Worksite-based health promotion programs, designed to both improve employee health and reduce employee health-related costs to sponsoring employers, are prime targets for accounting analyses of program success. Indeed, differential cost analyses techniques may be adapted to the measurement of program effectiveness in financial terms. This study suggests that numerous potential stumbling blocks exist to effective accounting analyses of corporate health promotion efforts. In essence, the task involves accurately measuring behavioral change associated with participation in designated health promotion activities, monetarizing measured behavioral changes, then comparing monetarized changes with associated program costs. Invariably, accountants will find this process challenging in that it requires the dissemination of knowledge not normally within the purview of the accounting profession.
- Published
- 1988
44. The Authors' Reply.
- Author
-
Kapoor, Alok, Radhakrishnan, Nila, and Smith, Kenneth J.
- Subjects
ANTICOAGULANTS ,COST effectiveness ,QUALITY standards ,COMMUNICATION criticism - Abstract
The article presents the authors' response following the critique of their work disagreeing their conclusion on the limited evidence of cost effectiveness on oral anticoagulants. The authors argue with the statement of Great Britain's National Institute for Health and Clinical Excellence (NICE) on the cost effectiveness of rivarobaxan emphasizing the vagueness of the comparator in the NICE statements. They note the scope of their search and clarifies the conclusion of their review.
- Published
- 2010
- Full Text
- View/download PDF
45. COST-EFFECTIVENESS OF CORONARY ARTERY BYPASS GRAFTING (CABG) VERSUS PERCUTANEOUS CORONARY INTERVENTION (PCI) IN SEVERE STABLE ISCHEMIC CARDIOMYOPATHY: A COMPARATIVE ANALYSIS.
- Author
-
Fatima, Shumail, Hickey, Gavin W., and Smith, Kenneth
- Subjects
- *
CORONARY artery bypass , *PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *CARDIOMYOPATHIES , *COST effectiveness , *COMPARATIVE studies - Published
- 2024
- Full Text
- View/download PDF
46. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
- Author
-
Altawalbeh, Shoroq M., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.
- Subjects
- *
PNEUMOCOCCAL vaccines , *RACIAL inequality , *COST effectiveness , *ECONOMIC aspects of diseases , *QUALITY-adjusted life years , *EUGENICS - Abstract
This study assesses the impact of expanding pneumococcal vaccination to all 50-year-olds to decrease racial disparities by estimating from the societal perspective, the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) and 15-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (PCV15/PPSV23) for 50-year-olds. A Markov model compared the cost-effectiveness of PCV20 or PCV15/PPSV23 in all general population 50- and 65-years-olds compared with current US recommendations and with no vaccination in US Black and non-Black cohorts. US data informed model parameters. Pneumococcal disease societal costs were estimated using direct and indirect costs of acute illness and of pneumococcal-related long-term disability and mortality. Hypothetical 50-year-old cohorts were followed over their lifetimes with costs and effectiveness discounted 3% per year. Deterministic and probabilistic sensitivity analyses assessed model uncertainty. In Black cohorts, PCV20 for all at ages 50 and 65 was the least costly strategy and had greater effectiveness than no vaccination and current recommendation strategies, whereas PCV15/PPSV23 at 50 and 65 cost more than $1 million per quality-adjusted life year (QALY) gained compared with PCV20 at 50 and 65. In non-Black cohorts, PCV20 at 50 and 65 cost $62 083/QALY and PCV15/PPSV23 at 50 and 65 cost more than $1 million/QALY with current recommendations, again being more costly and less effective. In probabilistic sensitivity analyses, PCV20 at 50 and 65 was favored in 85.7% (Black) and 61.8% (non-Black) of model iterations at a $100 000/QALY gained willingness-to-pay threshold. When considering the societal costs of pneumococcal disease, PCV20 at ages 50 and 65 years in the general US population is a potentially economically viable strategy, particularly in Black cohorts. • Some data support the cost-effectiveness of general population pneumococcal vaccination of all 50-year-olds in Black and non-Black cohorts compared with risk-based vaccination from the healthcare perspective. However, little is known about the cost-effectiveness of vaccinating all 50-year-olds from the societal perspective. • This study showed that 20-valent pneumococcal conjugate vaccine at ages 50 and 65 years was an economically favorable vaccination strategy from the societal perspective. Findings were especially favorable in the Black population. • Recommending pneumococcal vaccination for general population 50-year-olds warrants consideration if reducing pneumococcal disease disparities in underserved minorities is a priority. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
- Author
-
Altawalbeh, Shoroq M., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.
- Subjects
- *
PNEUMOCOCCAL vaccines , *VACCINATION of children , *STREPTOCOCCAL diseases , *ADULTS , *COST effectiveness - Abstract
Indirect effects of childhood pneumococcal conjugate vaccines (PCV) have diminished the cost-effectiveness of current adult vaccine recommendations. An in-development adult-formulated 21-valent pneumococcal conjugate vaccine (PCV21) may play a critical role in reducing pneumococcal illness by targeting a larger number of serotypes responsible for adult pneumococcal infections. This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, with and without considering childhood pneumococcal vaccination indirect effects. Model parameters were based on US data. Parameter uncertainty was assessed using 1-way and probabilistic sensitivity analyses. From the societal perspective, PCV21 at ages 50/65 years compared to PCV21 at age 50 years cost $7,410 per quality adjusted life year (QALY) gained in Black cohort analyses and $85,696/QALY gained in the non-Black cohort; PCV21 at ages 50/65 years had the most favorable public health outcomes. From the healthcare perspective, compared to no vaccination, PCV21 at age 50 years cost $46,213/QALY gained in the Black cohort and $86,629/QALY in non-Blacks. All other strategies were dominated in both cohorts and from both perspectives. When considering childhood pneumococcal vaccination indirect effects, costs of PCV21 at ages 50/65 years remained less than $140,000/QALY gained from the societal perspective in both populations. PCV21 is potentially cost-effective compared to currently approved pneumococcal vaccines in adults aged 50 years or older from both the societal and healthcare perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Reply to: Estimating the Full Value of High-Dose Influenza Vaccine.
- Author
-
Raviotta, Jonathan M., Smith, Kenneth J., DePasse, Jay, Brown, Shawn T., Shim, Eunha, Nowalk, Mary Patricia, and Zimmerman, Richard K.
- Subjects
- *
VACCINE effectiveness , *INFLUENZA vaccines , *INFLUENZA prevention , *COST effectiveness , *MATHEMATICS , *STATISTICAL models , *OLD age - Published
- 2017
- Full Text
- View/download PDF
49. A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children.
- Author
-
Shaikh, Nader, Dando, Emily E., Dunleavy, Mark L., Curran, Dorothy L., Martin, Judith M., Hoberman, Alejandro, and Smith, Kenneth J.
- Abstract
Objective: To assess whether antimicrobial therapy in young children with acute otitis media reduces time to resolution of symptoms, overall symptom burden, and persistence of otoscopic evidence of infection. We used a cost-utility model to evaluate whether immediate antimicrobial treatment seems to be worthwhile, and if so, which antimicrobial agent is most cost effective.Study Design: We compared the cost per quality-adjusted life-day of 5 treatment regimens in children younger than 2 years of age with acute otitis media: immediate amoxicillin/clavulanate, immediate amoxicillin, immediate cefdinir, watchful waiting, and delayed prescription (DP) for antibiotic.Results: The 5 treatment regimens, listed in order from least effective to most effective were DP, watchful waiting, immediate cefdinir, immediate amoxicillin, and immediate amoxicillin/clavulanate. Listed in order from least costly to most costly, the regimens were DP, immediate amoxicillin, watchful waiting, immediate amoxicillin/clavulanate, and immediate cefdinir. The incremental cost-utility ratio of immediate amoxicillin compared with DP was $101.07 per quality-adjusted life-day gained. The incremental cost-utility ratio of immediate amoxicillin/clavulanate compared with amoxicillin was $2331.28 per quality-adjusted life-day gained.Conclusions: In children younger than 2 years of age with acute otitis media and no recent antibiotic exposure, immediate amoxicillin seems to be the most cost-effective initial treatment. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
50. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
- Author
-
Altawalbeh, Shoroq M., Alshogran, Osama Y., and Smith, Kenneth J.
- Subjects
- *
APIXABAN , *ATRIAL fibrillation treatment , *WARFARIN , *DRUG therapy , *ANTICOAGULANTS , *STROKE prevention , *FIBRINOLYTIC agents , *ATRIAL fibrillation , *BLOOD coagulation , *CHRONIC kidney failure , *COMPARATIVE studies , *COST effectiveness , *GLOMERULAR filtration rate , *HEART , *HETEROCYCLIC compounds , *HOSPITAL care , *KIDNEYS , *RESEARCH methodology , *MEDICAL care costs , *MEDICAL cooperation , *PYRIDINE , *QUALITY of life , *RESEARCH , *STROKE , *EVALUATION research , *TREATMENT effectiveness , *QUALITY-adjusted life years , *DISEASE complications , *ECONOMICS , *THERAPEUTICS ,THERAPEUTIC use of fibrinolytic agents ,CHRONIC kidney failure complications - Abstract
Background: Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.Objectives: To evaluate the cost-utility of apixaban compared with warfarin in AF patients at different levels of kidney function.Methods: A Markov model was used to estimate the cost effectiveness of apixaban compared with warfarin in AF patients at three levels of kidney function: estimated glomerular filtration rate (eGFR) of more than 80 ml/min, 50 to 80 ml/min, and 50 ml/min or less. Event rates and associated utilities were obtained from previous literature. The model adopted the US health care system perspective, with hospitalization costs extracted from the Healthcare and Utilization Project. Treatment costs were obtained from official price lists. Univariate and probabilistic sensitivity analyses were performed to evaluate the robustness of results.Results: Apixaban was a dominant treatment strategy compared with warfarin in AF patients with eGFR levels of 50 ml/min or less and 50 to 80 ml/min. In patients with an eGFR of more than 80 ml/min, apixaban was cost-effective compared with warfarin, costing $6307 per quality-adjusted life-year gained. Results were consistent assuming anticoagulant discontinuation after major bleeding events. Compared with dabigatran and rivaroxaban, apixaban was the only cost-effective anticoagulant strategy relative to warfarin in both mild and moderate renal impairment settings.Conclusions: Apixaban is a favorably cost-effective alternative to warfarin in AF patients with normal kidney function and potentially cost-saving in those with renal impairment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.